Pacific Biosciences of California, Inc.
PACBPacific Biosciences of California, Inc. (a.k.a. PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PACB Earnings Report
EPS Est: $-0.14 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is Pacific Biosciences of California, Inc.'s next FDA catalyst?→
Pacific Biosciences of California, Inc.'s (PACB) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PACB biotech catalysts?→
Add PACB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pacific Biosciences of California, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.